Pharmacovigilance is under pressure to evolve.
The necessity to change is fueled by regulatory agencies wanting to strive to better protect the patient, as well as Sponsors having to deal with soaring ICSR needs and increasingly complex global operations.
Digital innovation is the key to transformation.
From harnessing technology advancements and the significantly increasing data volumes - across clinical trials, to real-world sources, the industry has increased its digital efforts over the past year and is discussing early pilots to understand how to apply technology to bring about new ways of working.
There are significant roadblocks and concerns that may prove to make it a bumpy road ahead. Read our white paper to learn more.